Patrick Campbell

Explore five pivotal FDA decisions set for early 2026 that could transform specialty medicine and enhance treatment options across various conditions.

Recent studies reveal belimumab's effectiveness in treating lupus nephritis, showing significant renal response and improved patient outcomes in real-world settings.

New analysis reveals obinutuzumab's potential to improve kidney inflammation and biomarkers in lupus nephritis.

Data from the POETYK PsA-2 trial examining deucravacitinib were presented at the 2025 American Academy of Dermatology annual meeting.

Use of obinutuzumab was associated with significant improvements in complete renal response rate and markers of disease activity in active lupus nephritis.

Announced on September 18, 2024, the approval of benralizumab for adults with EGPA, which is based on the MANDARA trial, marks the second FDA approval for EGPA.

A new study using FDA's Sentinel System found no significant association between recombinant zoster vaccine and incident gout in adults aged 50+.

A review of the 20 novel drugs approved by the US Food and Drug Administration during the first half of 2024, with links to coverage from MJH Life Sciences publications.

EULAR 2024 data link maternal intake of over 252 grams of fish per week with higher risk of juvenile idiopathic arthritis in offspring, but causation is unclear.

A study from EULAR details the ability of the FIRST self-questionnaire to identify fibromyalgia in patients with rheumatoid arthritis.

An analysis of the REALISTIC trial from EULAR 2024 details the effects of certolizumab pegol in rheumatoid arthritis based on rheumatoid factor levels and prior TNF inhibitor use.

A propensity score matched analysis suggests use of SGLT2 inhibitors could reduce risk of negative outcomes in patients with systemic lupus erythematosus and type 2 diabetes.

An analysis of CDC WONDER data details disparities among the cardiovascular mortality rate for patients with rheumatoid arthritis in the US.

New analysis suggests use of high-dose etanercept may help children with juvenile idiopathic arthritis achieve remission and reduce disease activity.

Patients with systemic autoimmune/inflammatory rheumatic diseases were nearly 3 times more likely to receive opioid prescriptions from 2006 to 2019.

An analysis of more than 1800 adults with psoriatic arthritis found more than 20% of patients report widespread pain, with 10% meeting fibromyalgia criteria.

A real-world study from Spain suggests baricitinib demonstrated favorable effectiveness, adherence, and safety in rheumatoid arthritis, but investigators caution more research is needed.

FDA approves label update for voclosporin (Lupkynis) in lupus nephritis, reflecting long-term AURORA data and new kidney function monitoring guidance.

A propensity score-matched, new-user analysis suggests SGLT2 inhibitors may reduce gout risk in type 2 diabetes patients relative to other second-line therapies.

Almost 50% of fibromyalgia patients use cannabis for symptom relief, according to new study. Experts suggest results underline need for clinician awareness, further research.

An analysis of data from more than 5 million people suggests rheumatic and immune-mediated diseases were associated with increased rates of childlessness and elevated risk of adverse pregnancy outcomes.

On March 11, 2024, Acelyrin Inc. announced new positive data from clinical trial programs examining their IL-17A inhibitor izokibep in patients psoriatic arthritis and hidradenitis suppurativa.

A study from Brigham and Women's Hospital has identified 6 blood-based biomarkers that may predict cardiovascular disease risk in rheumatoid arthritis patients.

A recent study points to a link between bisphenol exposure and elevated uric acid levels, with implications for gout risk, especially in women.

A Finnish study finds elevated cardiovascular risk in rheumatic diseases peaks within a year of diagnosis, emphasizing the need for early management strategies.

In a study involving over 500 children, artificial intelligence using echocardiography demonstrated accuracy comparable to expert cardiologists in detecting rheumatic heart disease, hinting at the prospect of a potentially transformative tool for early intervention and disease prevention.

On January 19, 2024, the FDA announced the addition of a Boxed Warning to the labeling of denosumab (Prolia), citing evidence of an increased risk of severe hypocalcemia in patients with chronic kidney disease.

Richard Johnson, MD, discusses the results of a study from ASN Kidney Week 2023 detailing the effects of urate-lowering therapy on blood pressure among patients with gout.

An analysis of data from 26 patients with repeat kidney biopsies in the AURORA program suggests voclosporin (Lupkynis) reduces proteinuria without causing harm in lupus nephritis patients.

An analysis of the MIRROR trial from ASN Kidney Week 2023 details the effects of urate-lowering therapy on blood pressure among patients with uncontrolled gout receiving pegloticase plus methotrexate in the phase 4 trial.